Ziprasidone in the Psychosis Prodrome

Completed · Phase 2 · Has a placebo group

Conditions studied: Psychosis Prodrome

In brief

This study aims to determine whether ziprasidone is superior to placebo over 24 weeks for patients with the psychosis prodrome.

Key facts

Study ID

NCT00635700

Run by

Yale University

People needed

51

Starts

2008-03-01

Expected to finish

2012-11-01

Last updated by the study team

2023-03-27

Who can join

Age: 16 and older, up to 40. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Structured Interview for Psychosis-risk Syndromes criteria for Clinical High Risk for Psychosis
• clinically referred

You may not qualify if…

• prolonged corrected QT interval
• history of syncope

Where it is running

• University of California at San Diego — La Jolla, California, United States
• University of California at Los Angeles — Los Angeles, California, United States
• University of California, San Francisco — San Francisco, California, United States
• Yale University School of Medicine — New Haven, Connecticut, United States
• Emory University — Atlanta, Georgia, United States
• Beth Israel Deaconess Hospital — Boston, Massachusetts, United States
• University of Massachusetts — Worcester, Massachusetts, United States
• Wayne State University School of Medicine — Detroit, Michigan, United States
• North Shore, Long Island Jewish Health System — Glen Oaks, New York, United States
• University of North Carolina — Chapel Hill, North Carolina, United States
• University of Calgary — Calgary, Alberta, Canada

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.